NOVARTIS for NOVARTIS
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
ACA Pharmaceutical Industry Fee Exclusions Anti-Inversion Tax Medical Device Tax Repeal & Suspension Section 385 Tax Regulation Tax Reform Orphan Drug Tax Tax Reform Border Adjustment Tax
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| SHAWN O'NEAIL | — |
| CANDICE PHIPPS | — |
Veterans VET
Veterans Affairs National Pharmaceutical Bid
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India, China and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines . Trade Promotion Authority . Trans-pacific Partnership . Trans Atlantic Trade and Investment Partnership International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies Colombia Intellectual Property Regulatory Cooperation The North American Free Trade Agreement - NAFTA USTR Special 301 Report/National Trade Estimate
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| SHAWN O'NEAIL | — |
| CANDICE PHIPPS | — |
Copyright/Patent/Trademark CPT
Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Patient Litigation Reform and Issues Related to Post Grant Proceedings at PTO Neonates BPCIA Hatch-Waxman Patents
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| SHAWN O'NEAIL | — |
| CANDICE PHIPPS | — |
Health Issues HCR
Cell & Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Biosimilars PDUFA Low-income Subsidy in Part D REMS Creates Act FCLCA Value of Medicines Drug Cost/Pricing Biosimilars Reimbursement Generic Drugs Medicaid FDA Regulations of Lab Developed Tests (LDT) Reimbursement for LDTs Part B Demo IPAB Generic Drug Labeling Outcomes-based Contracting Expanded Access PREA/BPCA BSUFA GDUFA Truthful, Non-Misleading Drug Information Part D Non-interference S.469 - Affordable and Safe Prescription Drug Importation Act Orphan Drugs Drug Pricing Transparency S.456 - RACE for Children Act S.204 - Trickett Wendler Right to Try Act of 2017
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| SHAWN O'NEAIL | — |
| CANDICE PHIPPS | — |
| WENDY P SUSSMAN | — |
Medicare/Medicaid MMM
Biosimilars Medicare Part D Drug Pricing Part B CMMI Part B Demonstration Project Generics Innovative Pharmaceuticals
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| SHAWN O'NEAIL | — |
| CANDICE PHIPPS | — |
| WENDY P SUSSMAN | — |
Budget/Appropriations BUD
FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2017 Labor HHS Appropriations Bill Reconciliation Gx Drug Labeling Biosimilars
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| LEO A FARBER | — |
| SHAWN O'NEAIL | — |
| CANDICE PHIPPS | — |
| WENDY P SUSSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.